A multiscale pharmacokinetic-Boolean modelling framework for ibrutinib resistance in a Chronic Lymphocytic Leukaemia case study
Ibrutinib, a covalent Bruton's tyrosine kinase (BTK) inhibitor, achieves durable remissions in chronic lymphocytic leukaemia (CLL), and yet a substantial p